Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
123 studies found for:    Kaiser Permanente | Open Studies | cancer
Show Display Options
Download search resultsDownload the search results for:
Kaiser Permanente | Open Studies | cancer (123 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Not yet recruiting Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Condition: Prostate Cancer
Intervention: Procedure: MRI UroNav fusion biopsy
2 Recruiting Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Condition: Colorectal Cancer
Intervention: Other: Auto Plus
3 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Lung Carcinoid Tumor;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
4 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
5 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Cholangiocarcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Hilar Cholangiocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Stage II Gallbladder Cancer;   Stage III Childhood Hepatocellular Carcinoma;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Hepatocellular Carcinoma;   Stage IV Distal Bile Duct Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Trametinib;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis
6 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
7 Recruiting Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: anti-B7H1 monoclonal antibody MEDI4736;   Drug: PI3 kinase inhibitor GDC-0032;   Drug: palbociclib isethionate;   Drug: FGFR inhibitor AZD4547;   Biological: rilotumumab;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
8 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
9 Recruiting Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
Conditions: Cervical Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Perioperative/Postoperative Complications;   Radiation Toxicity;   Urinary Complications;   Urinary Tract Toxicity
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
10 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
11 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
12 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
13 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
14 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
15 Recruiting Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
16 Recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
17 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
18 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
19 Recruiting Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Conditions: Breast Cancer;   Lymphedema;   Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention;   Other: educational intervention;   Procedure: assessment of therapy complications;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
20 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years